Clinical outcomes of direct‐acting antiviral treatments for patients with hepatitis C after hepatocellular carcinoma are equivalent to interferon treatment

Aim It remains unclear how direct‐acting antiviral (DAA) treatments influence hepatocellular carcinoma (HCC) recurrence and survival in comparison with interferon (IFN). Methods In total, 338 patients with chronic hepatitis C virus (HCV) infection and previous HCC treatments who initiated IFN ( N = 88, IFN group) or DAA treatment ( N = 250, DAA group) from January 2005 to November 2017 at 23 hospitals and achieved sustained virologic response...